Akari Therapeutics plc filings document the regulatory record of an England and Wales biotechnology issuer whose ordinary shares trade on Nasdaq only in connection with American Depositary Shares. The company’s SEC disclosures cover S-1 registration statements, 8-K material-event reports, proxy materials, and shareholder voting results tied to its ADS and ordinary-share structure.
Akari’s filings describe securities offerings, private placements, warrants, note exchanges, ADS ratio matters, Nasdaq listing-rule approvals, and amendments affecting share capital. Proxy and meeting materials also document U.K. public-company governance, quorum and voting mechanics, security-holder rights, and approvals related to the company’s capital structure.
Akari Therapeutics Plc (AKTX) director Raymond Prudo-Chlebosz was granted 9,072 American Depositary Shares (ADSs) representing restricted stock units on August 18, 2026, and 3,240 ADSs on October 5, 2026, in lieu of accrued but unpaid cash retainers payable to non-executive directors. Both RSU awards are subject to forfeiture if shareholder approval of a proposed amendment increasing shares reserved under the equity incentive plan is not obtained, and vest in full on approval. He was also granted options for 30,000 ADSs and 15,000 ADSs on August 18, 2026, each with a $7.899 exercise price; vesting depends on approval and continued service.
Akari Therapeutics Plc reported direct awards to director and 10% owner Hoyoung Huh: an RSU award reported for 17,249 ADSs on August 18, 2026, and one for 6,160 ADSs on October 5, 2026. Both were granted in lieu of accrued but unpaid cash retainers payable to directors, are subject to forfeiture if Shareholder Approval of a proposed equity incentive plan amendment to increase the plan’s share reserve is not obtained, and vest in full on the approval date. On August 18, 2026, Huh also received options covering 30,000 ADSs and 15,000 ADSs, each with a $7.8990 exercise price and subject to the same approval condition. The options have different vesting schedules, require continued service on each vesting date, and expire August 18, 2036.
Akari Therapeutics Plc (AKTX) director Sandip I. Patel reported exercising pre-funded warrants covering 3,866 ADSs and 6,186 ADSs on October 14, 2026, at an exercise price of $0.0004 per ADS. He also reported awards of RSUs representing 12,100 ADSs on August 18, 2026, and 4,313 ADSs on October 5, 2026, granted in lieu of accrued but unpaid cash retainers under the issuer’s remuneration policy. The RSUs are subject to forfeiture if shareholder approval of a proposed equity-plan amendment is not obtained and vest in full upon approval. Patel also received options to purchase 45,000 ADSs and 15,000 ADSs on August 18, 2026, each with a $7.8990 exercise price and an expiration date of August 18, 2036. Both option grants are subject to forfeiture if shareholder approval is not obtained and have separate vesting schedules.
Akari Therapeutics Plc director Robert B. Bazemore reported exercising pre-funded warrants for 773 and 3,093 ADSs on October 14, 2026, acquiring corresponding American Depositary Shares at an exercise price of $0.0004 per ADS; the related warrant positions were reported as disposed. The warrants became exercisable upon shareholder approval obtained March 2, 2026.
He also received awards of 13,100 ADSs representing restricted stock units on August 18, 2026, and 4,677 ADSs representing restricted stock units on October 5, 2026. The RSUs were granted in lieu of accrued but unpaid cash retainers in accordance with the Company's remuneration policy. They will vest in full upon shareholder approval of a proposed equity incentive plan amendment and are subject to forfeiture if approval is not obtained. On August 18, 2026, he also received options to purchase 45,000 and 15,000 ADSs, each with a $7.899 exercise price and an August 18, 2036 expiration date; those options are also subject to forfeiture if approval is not obtained.
Akari Therapeutics Plc CEO Abizer Gaslightwala exercised pre-funded warrants on October 14, 2026, acquiring 19,333 ADSs and 7,733 ADSs at an exercise price of $0.0004 per ADS. The warrants became exercisable upon shareholder approval obtained March 2, 2026. On August 18, 2026, he was granted options to purchase 174,000 ADSs at $7.899 per ADS, expiring August 18, 2036; the grant is subject to forfeiture if shareholder approval of a proposed equity-plan amendment is not obtained, and vesting is subject to continued service.
Akari Therapeutics Plc director Samir Rashmikant Patel received 6,300 ADSs as RSUs on August 18, 2026, and 2,236 ADSs on October 5, 2026; both were granted in lieu of accrued but unpaid cash retainers. The RSUs and options are subject to forfeiture if shareholders do not approve a proposed equity-plan amendment; RSUs vest in full upon approval. On August 18, Patel received options for 30,000 and 15,000 ADSs, each exercisable at $7.8990 per ADS and expiring August 18, 2036; option vesting also requires approval and continued service.
Akari Therapeutics Plc (AKTX) Chief Business Officer Vat-Ho Vatnak received an option grant to purchase 87,000 ADSs. The award transaction is dated October 12, 2026; the stated Grant Date is October 5, 2026. The options have an exercise price of $8.94 per ADS and are subject to forfeiture and cancellation if shareholders do not approve a proposed increase in the equity plan’s share reserve. They vest 25% on the Grant Date’s 12-month anniversary, then in equal monthly installments over the next 36 months, subject to continued service, with full vesting on the 4-year anniversary.
Akari Therapeutics Plc asks shareholders to approve a 144,000,000,000-ordinary-share increase in the 2023 Equity Incentive Plan reserve, from 19,806,000,000 to 163,806,000,000 ordinary shares. The proposal also permits up to 855,637,300 ordinary shares tied to 2014 Plan awards that are forfeited or cancelled, or expire unexercised. The Board approved the increase subject to shareholder approval at the October 28, 2026 meeting and says the expanded pool would support long-term equity incentives for employees, consultants and directors.
As of October 1, 2026, 16,272,945,001 ordinary shares were subject to outstanding options under the 2023 and 2014 Plans, at a weighted average exercise price of $0.00055; 1,200,000,000 shares were subject to unvested, performance-based restricted stock units, and 484,739,210 shares remained available under the 2023 Plan. Akari reported 182,813,169,533 issued and outstanding ordinary shares as of September 30, 2026. Ordinary-share proxy forms are due to Equiniti by 2:30 p.m. London time on October 26, 2026; ADS proxy cards are due to Deutsche Bank by 1:00 p.m. Eastern Time on October 19, 2026. The Board unanimously recommends voting FOR.
Akari Therapeutics Plc CEO Abizer Gaslightwala received a direct award of 6,430 American Depositary Shares representing ordinary shares on September 29, 2026, at a reported $9.72 per share; his reported direct holdings afterward were 14,107 shares. The associated RSUs vest in four approximately equal quarterly installments, subject to continued service, and are subject to forfeiture and cancellation if shareholders do not approve an amendment increasing the equity incentive plan's share reserve.